will they stop making tirzepatide A Major GLP-1 Drug Shortage Is Over. Some Patients Aren't Celebrating The recent announcement that Tirzepatide

The first animal studies showing that GLP-1 potentially had effects on the CV system was published in 2002, and the first study to show cardioprotection was in 2008 (102, 211), but it was not until the LEADER cardiovascular outcomes trial (CVOT) with liraglutide, published in 2016, that a reduction in CV risk with a GLP-1RA was documented (100)

Clinical trials have generally observed patients for weeks or months

Scientists are still studying the exact causes, but these medications appear to change how your digestive system works

Ready to detox, refresh, and glow

The 30 g dose was chosen based on previous studies by our group [18, 19]

It has been associated with complications from diabetic retinopathy